Yifan Pharmaceutical Valuation

Q: What is the Fair Price of 002019 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002019 (CN¥12.71) is trading above our estimate of [[fair value]] (CN¥3.18)

Is 002019 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002019 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002019 (CN¥12.71) is trading above our estimate of fair value (CN¥3.18)

Significantly Below Fair Value: 002019 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002019?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 002019. This is calculated by dividing 002019's market cap by their current preferred multiple.
What is 002019's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

002019 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.4x
Enterprise Value/EBITDA	39.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 002019's PS Ratio compare to its peers?

The above table shows the PS ratio for 002019 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7x
600129 Chongqing Taiji Industry(Group)Ltd	1.1x	14.1%	CN¥15.6b
000766 Tonghua Golden-Horse Pharmaceutical Industry CoLtd	10x	n/a	CN¥15.1b
603456 Zhejiang Jiuzhou Pharmaceutical	3x	13.8%	CN¥14.8b
300357 Zhejiang Wolwo Bio-Pharmaceutical	14x	20.8%	CN¥12.7b
002019 Yifan Pharmaceutical	3.1x	16.5%	CN¥15.5b

Price-To-Sales vs Peers: 002019 is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (7x).

Price to Earnings Ratio vs Industry

How does 002019's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.2%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 002019 is good value based on its Price-To-Sales Ratio (3.1x) compared to the CN Pharmaceuticals industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is 002019's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002019 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.1x
Fair PS Ratio	4.5x

Price-To-Sales vs Fair Ratio: 002019 is good value based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (4.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.